(TOR-ih-PA-lih-mab)
This page contains brief information about toripalimab-tpzi and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Toripalimab-tpzi is approved to treat:
- Nasopharyngeal carcinoma (a type of head and neck cancer). It is used:
- With cisplatin and gemcitabine hydrochloride as the first treatment in adults whose cancer has spread to other parts of the body or has come back in nearby tissues.
- Alone in adults whose cancer has come back and cannot be removed by surgery or has spread to other parts of the body and has been treated with platinum chemotherapy that did not work or is no longer working.
Toripalimab-tpzi is also being studied in the treatment of other types of cancer.
More About Toripalimab-tpzi
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Toripalimab Becomes First Immunotherapy Drug Approved for Nasopharyngeal Cancer
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Toripalimab-tpzi – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
